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AbstrACt
Objective and methods: It is rare that trialists report power 
estimations of non-primary outcomes. In the present 
article, we will describe how to define a valid hierarchy of 
outcomes in a randomised clinical trial, to limit problems 
with Type I and Type II errors, using considerations on the 
clinical relevance of the outcomes and power estimations. 
Conclusion: Power estimations of non-primary outcomes 
may guide trialists in classifying non-primary outcomes 
as secondary or exploratory. The power estimations 
are simple and if they are used systematically, more 
appropriate outcome hierarchies can be defined, and trial 
results will become more interpretable.
To avoid problems with Type I errors (false 
rejection of a true null hypothesis) and Type 
II errors (false acceptance of a null hypoth-
esis), and rash interpretations of the results 
of a randomised clinical trial, it is essential to 
(1) limit the number of outcomes;1 (2) adjust 
CIs and thresholds for significance according 
to number of outcome comparisons;1 and (3) 
define an outcome hierarchy (outcomes clas-
sified according to their type and how they 
ought to become interpreted).
Clinical success has many aspects and both 
beneficial and harmful effects ought to be 
interpreted, so selecting a single outcome 
variable is rarely feasible.1 We have previously 
summarised how to adjust CIs and thresholds 
for significance if there are multiple outcome 
comparisons.1 The European Medicines 
Agency has recently, conservatively and wisely, 
suggested using Bonferroni corrections.2
The present paper will describe how to 
define a valid hierarchy of outcomes in a 
randomised clinical trial, to limit problems 
with Type I and Type II errors, using power 
estimations of the non-primary outcomes. 
Our focus in the present paper is the overall 
outcome of a trial. Therefore, a Type I error 
will be defined as the case when the overall 
conclusion of a trial is that an intervention is 
effective—when it is not. Type II error will be 
defined as the case when the overall conclu-
sion of a trial is that an intervention is not 
effective—when it is. In order to maintain 
simplicity, we will focus on dichotomous and 
continuous outcomes, but the described prin-
ciples may be used for most other types of 
outcomes as well.3
summAry of fundAmentAl ConsiderAtions 
when defining outCome hierArChies in 
rAndomised CliniCAl triAls
Before considering power estimations 
of non-primary outcomes, we will briefly 
summarise what we believe are fundamental 
and essential considerations when defining 
outcome hierarchies in randomised clinical 
trials.
It is recommended to prespecify primary 
and secondary outcomes, including how and 
when they are assessed (http://www. consort- 
statement. org/ checklists/ view/ 32-- consort- 
2010/ 80- outcomes).3
To limit problems with multiplicity and 
difficulties with interpreting the trial results, 
it is often optimal to use only one primary 
outcome and the sample size should be based 
on this outcome.1 The primary outcome 
in a randomised clinical trial should be the 
outcome with the highest degree of clinical 
relevance for the patients, that is, patient 
centred outcomes. All primary and secondary 
outcomes in a randomised clinical trial should 
either be outcomes that are important for 
the decision to use the intervention or suffi-
ciently validated surrogate outcomes for such 
important outcomes.2 4 5 History has shown us 
that we cannot rely on surrogate outcomes, 
unless they are validated.4 The most-often 
cited example is the Cardiac Arrhythmia 
Suppression Trial (known as CAST), in which 
two drugs that suppressed ventricular arrhyth-
mias (a surrogate outcome correlated with a 
bad prognosis) were initially approved by the 
Food and Drug Administration, only to have 
the CAST demonstrate that, compared with 
placebo, individuals who had arrhythmias 
after myocardial infarctions and received 
antiarrhythmic drugs were 2.5 times as likely 
to die.6 It is necessary to validate a surrogate 
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outcome before we can be confident that it can be used 
in clinical trials or practice.4 7 Such validation requires 
randomised clinical trials that assess both the surrogate 
and clinical outcome and show that both are changed by 
the intervention in a comparable manner.4 7 8 Moreover, 
a validated surrogate for one drug cannot guarantee that 
the surrogate outcome will not mislead when new drugs 
are being tested.8 Non-validated surrogate outcomes 
should always be classified as ‘exploratory outcomes’, 
until formal validation has been proved and accepted by 
the scientific community.
When planning a randomised clinical trial, it is essen-
tial to estimate the required sample size.1 9–11 However, 
the majority of randomised clinical trials have difficulties 
in obtaining the stipulated sample size,12 and trials with 
too small sample sizes often suggest intervention effect 
sizes far from the ‘true’ effect sizes shown in subsequent 
larger trials and meta-analyses.1 13 Even most Cochrane 
systematic reviews with meta-analyses do not have suffi-
cient power.14 15
Power estimations of non-primary outcomes
Consider a single randomised clinical trial. If the esti-
mated sample size has not been reached, the risks of Type 
I errors (false rejection of the null hypothesis) and Type 
II errors (false acceptance of the null hypothesis) should 
be estimated when interpreting the trial results.1 16 The 
threshold for statistical significance (and consequently the 
CI) should be adjusted to the fraction of the preplanned 
number of participants randomised.1 16 Clearly, there is 
no safeguard against all kinds of bias, but adjustment 
schemes in common use at the very least protect against 
the dangers of premature or repeated testing.1 Such 
adjustments should, ideally, be common practice in all 
high quality trials.1 16
Analogous problems arise with non-primary outcomes 
when the information is deemed insufficient; that is, 
when statistical power is not known, the data cannot 
unreservedly be analysed as if based on a dataset large 
enough to draw conclusions about a minimal important 
difference (MID).17 If MID effect estimates, as well as null 
effect, are included in the naïve 95% CI, then this indi-
cates that more information may be needed. However, if 
MID effect estimates are not included in the naïve 95% 
CI, then it is unclear if more data are needed to uncover 
a worthwhile effect or if there is in fact no worthwhile 
difference between the groups.1
When null effect is excluded in the naïve 95% CI and 
it is unclear whether there is enough information, it will 
also be difficult to interpret the analysis results. Trial 
results tend to show spurious results of too beneficial or 
too harmful effect estimates if there is insufficient infor-
mation.1 Inspecting unadjusted naïve 95% CI when the 
sample size has not been reached will not suffice as such 
CIs would be inappropriately narrow, as stated above.1 16
In order to estimate the statistical power of an analysis, 
it is necessary to decide on an MID,1 17 an incidence in the 
control group when assessing a dichotomised outcome or 
a SD when assessing a continuous outcome, and an accept-
able risk of Type I error adjusted according to the number 
of outcome comparisons.1 2 Alternatively, the sequence in 
which the secondary outcomes are tested may be prespec-
ified and carried out without adjustment, but stopped 
when the first null hypothesis is not rejected after which 
the rest of the assessments will become exploratory.1 Most 
statistical software can easily estimate both sample sizes 
and power estimations of non-primary outcomes.18
Power analysis should be part of standard trial methodology
For the reasons stated above, we recommend at the 
protocol stage to estimate the statistical power of all 
non-primary outcomes for confirming or rejecting a 
MID. If the power is less than 80% (or 90%), then this 
outcome should be classified as an ‘exploratory outcome’ 
together with the non-validated surrogate outcomes.19 
Alternatively, the CI and the thresholds for significance 
for the outcome in question may be adjusted due to 
sparse data,1 16 or the sample size could be reconsidered 
and increased so the power of the non-primary outcome 
in questions becomes 80% (or 90%).1 16
We searched for all randomised clinical trials published 
in the British Medical Journal during 2017 and found 10. 
Only one randomised clinical trial briefly mentioned that 
‘A trial of this size will also give more than 80% power to 
detect important differences in secondary outcomes…’.20 
None of the remaining nine trials reported any consid-
erations of power of non-primary outcomes, and it is 
generally rare that trialists report power estimations of 
non-primary outcomes. As we have described, trial results 
always ought to be interpreted in the light of the required 
sample size and the obtained sample size, and without 
power estimations it will be difficult to make valid conclu-
sions based on non-primary outcome results. It is simple 
to estimate the power of outcome tests, so it is striking 
that this is not done regularly by trialists. Of course, MIDs 
(together with a measure of variance and an acceptable 
risk of Type I error) need to be estimated to estimate the 
power of an outcome comparison, which might seem 
troublesome. Nevertheless, MIDs need to be defined for 
all important outcomes regardless of the use of power 
estimations, otherwise it will be difficult to judge if statis-
tically significant results are also clinically meaningful for 
patients.1 All the necessary quantities (MIDs, estimations 
of proportion in the control group, SD) in the power 
estimations may possibly be estimated on the basis of a 
systematic review of studies, performed before the trial is 
conducted.
Considerations on the clinical relevance of outcomes 
and power estimations seem an important tool that may 
help defining appropriate outcome hierarchies. In addi-
tion to estimating a required sample size, we believe that 
future trialists when planning a randomised clinical trial, 
ought to estimate power of all non-primary outcomes 
and consider estimating power of subgroup comparisons. 
Power estimations of non-primary outcomes may guide 
trialists in classifying non-primary outcomes as secondary 
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or exploratory. The power estimations are simple and if 
they are used systematically, more appropriate outcome 
hierarchies can be defined, and trial results will become 
more interpretable.21
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